The Positive Side of Salmonella

Photo: James PlattFriends and colleagues: From left, K. Brooks Low, David Bermudes, John M. Pawelek When the public hears about Salmonella, it is usually in a warning about food poisoning, but a group of researchers in New Haven, Conn., is using the bacteria to target cancer. It turns out that Salmonella preferentially colonize and multiply within a tumor, thereby inhibiting growth. Vion Pharmaceuticals is taking advantage of this trait by genetically altering Salmonella typhimurium to reduce th

Written byNadia Halim
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Photo: James Platt

Friends and colleagues: From left, K. Brooks Low, David Bermudes, John M. Pawelek
When the public hears about Salmonella, it is usually in a warning about food poisoning, but a group of researchers in New Haven, Conn., is using the bacteria to target cancer. It turns out that Salmonella preferentially colonize and multiply within a tumor, thereby inhibiting growth. Vion Pharmaceuticals is taking advantage of this trait by genetically altering Salmonella typhimurium to reduce the serious toxicities associated with wild-type infection and create a novel cancer treatment.

The association between bacterial infection and tumor regression has existed since the turn of the century. William B. Coley, attending bone surgeon at Memorial Hospital, now Memorial Sloan-Kettering Cancer Center, noticed that patients who developed severe infections after surgery for sarcoma fared much better than those who did not develop postoperative infections. Based on these observations, Coley purified a component of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies